Scarab Genomics LLC is pleased to report the allowance of US Patent 11,174,284, “Purification of CRM 197 from bacteria”. CRM 197 is a “vaccine carrier protein” that is widely used to enhance the effectiveness of so-called “conjugate vaccines”, for example Pfizer’s Prevnar® and GSK’s Menveo® vaccines, which protect against pneumonia and meningitis respectively. CRM 197 […]
Scarab Genomics LLC is pleased to report the allowance of US Patent 10,604,736, “Materials and methods for extended continuous flow fermentation of reduced genome bacteria”. The patented technology, branded “C-Flow”, is poised to revolutionize biopharmaceuticals production, delivering increased efficiency, reliability, consistency and safety, while facilitating rapid process development, thereby reducing time to market. Many biopharmaceuticals […]
The success of conjugate vaccine technology, in which a highly immunogenic protein is linked to a poorly immunogenic antigen such as a small carbohydrate, is leading to the increased deployment of conjugate vaccines. However, once a patient is vaccinated with a conjugate vaccine, subsequent vaccination with other vaccines that use the same protein conjugate may […]
Nucleic acid vaccines are coming into their own following recent success with rapid development of effective vaccines against Covid-19. However, most E. coli strains used for nucleic acid production contain multiple IS elements that can transpose into the desired production sequence, compromising the product, or into the regulatory elements, compromising production. Use of Scarab Genomics’ […]
A CMO client was having difficulty producing single-chain antibodies using their standard E. coli fermentation processes. Scarab was asked to assist, and within six weeks of receiving the cloned gene for the antibodies, Scarab delivered samples of both antibodies to the client using the company’s Clean Genome® E. coli technology. This demonstrates not only Scarab’s […]